{"count":3,"limit":50,"offset":0,"edits":[{"id":47053,"actor_id":"codex:51","entity_type":"hypothesis","entity_id":"h-ec79168b","action":"update","diff_json":{"after":0.48,"before":0.0},"change_reason":"Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d8-a7f2-c17802c60840]","created_at":"2026-04-26T21:44:07.424021+00:00"},{"id":47054,"actor_id":"codex:51","entity_type":"hypothesis","entity_id":"h-ec79168b","action":"update","diff_json":{"after":"[data_support_backfill task:2ab61458-7bb9-47d8-a7f2-c17802c60840] data_support_score=0.480; evidence_component=0.36; kg_component=0.04; debate=0.10; analysis=0.10; contradiction_penalty=0.12; support_PMIDs=40883746,40060520,39814008,29686391,35040015 | contradicting_PMIDs=39814008,40883746,29686391 | kg_edges_generated=1;linked_KG=promoted-h-ec79168b | analysis=SDA-2026-04-15-gap-debate-20260410-112730-24052bbe\nprior_evidence_validation={\"total_evidence\": 11, \"pmid_count\": 8, \"papers_in_db\": 1, \"description_length\": 3262, \"has_clinical_trials\": false, \"has_pathway_diagram\": true, \"has_gene_expression\": false, \"issues\": []}","before":"{\"total_evidence\": 11, \"pmid_count\": 8, \"papers_in_db\": 1, \"description_length\": 3262, \"has_clinical_trials\": false, \"has_pathway_diagram\": true, \"has_gene_expression\": false, \"issues\": []}"},"change_reason":"Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d8-a7f2-c17802c60840]","created_at":"2026-04-26T21:44:07.424021+00:00"},{"id":3460,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-ec79168b","action":"update","diff_json":{"after":"## GPC4/HSPGs Collaborate with ApoE Isoforms to Dictate Tau Conformational Strain Uptake Efficiency\n\n### Heparan Sulfate Proteoglycans as Tau Uptake Regulators\n\nHeparan sulfate proteoglycans (HSPGs) are cell-surface molecules bearing heparan sulfate chains that interact with a wide variety of proteins. In the brain, HSPGs are expressed by neurons, glia, and vascular cells. The glypican (GPC) family, particularly GPC4, has emerged as a critical regulator of tau uptake and spreading.\n\nGPC4 is a GPI-anchored HSPG predominantly expressed in neurons during development and increasingly recognized for its role in adult brain lipid metabolism and protein trafficking. GPC4's heparan sulfate chains bind to multiple ligands including tau protein. The interaction between tau and GPC4/HSPGs is conformation-dependent, with different tau strains showing differential binding affinity.\n\n### The Conformational Strain Selector Model\n\nTau protein adopts multiple conformations (strains) that correlate with distinct disease phenotypes. The strain-selective uptake model proposes that HSPGs act as conformational selectors — certain HSPG structures preferentially uptake specific tau conformations, influencing which strain dominates in a given neuron or brain region.\n\nThe critical discovery is that APOE isoforms (APOE2, APOE3, APOE4) modulate the GPC4-tau interaction in a manner that affects both uptake efficiency and the conformational fate of internalized tau:\n\n1. **APOE4:** APOE4 has reduced lipid-binding capacity and altered interactions. When APOE4 is present, the GPC4-tau interaction becomes more permissive — tau uptake increases but the ability of APOE to chaperone tau into a degradation pathway is reduced. This leads to accumulation of conformationally intact tau strains that template the conversion of endogenous tau.\n\n2. **APOE3:** APOE3 maintains better lipid-binding and appears to channel internalized tau toward lysosomal degradation, reducing templated conversion.\n\n3. **APOE2:** APOE2 has the strongest lipid-binding but paradoxically shows reduced AD risk in some contexts.\n\n### Therapeutic Intervention Points\n\n**1. GPC4 Modulation:** Reducing GPC4 expression or blocking its HS chains would reduce tau uptake. ASO-mediated GPC4 knockdown in adult neurons could provide controlled reduction.\n\n**2. APOE Mimetic Peptides:** Small peptides that mimic the tau-binding domain of APOE but direct tau toward degradation could compete with endogenous APOE.\n\n**3. HSPG Sulfation Modulation:** Modulating the sulfation pattern of heparan sulfate chains (e.g., through NDST inhibitors) could shift the conformational selectivity of tau uptake.\n\n**4. Lysosomal Enhancement:** Improving lysosomal function through TFEB activation would increase degradation of tau conformers regardless of APOE-mediated routing.\n\n### Clinical Evidence\n\nAPOE4 carriers show increased CSF tau and faster tau accumulation on PET compared to APOE3 carriers. The convergence of APOE4 as an AD risk factor with the discovery of GPC4 as a tau uptake regulator provides a mechanistic framework for why APOE4 carriers have higher tau burden and faster disease progression. Biomarker strategies include CSF tau species measurement, PET tau imaging, and APOE isoform phenotyping.","before":"The synergy between GPC4 (glypican-4) heparan sulfate proteoglycans and APOE in tau uptake suggests these molecules form a conformational strain selector. Different tau strains have distinct binding affinities for APOE-GPC4 complexes, explaining why some conformers propagate more efficiently."},"change_reason":null,"created_at":"2026-04-16T17:18:16+00:00"}]}